W Blair Geho

This inventor holds 34 USPTO granted patents and 15 published patent applications, plus 4 CIPO patents and 3 EPO patents, primarily in Lipid-Based Drug Delivery. Top assignees: Sdg LLC, Technology Unlimited, Inc., Diasome Pharmaceuticals, Inc.. Active years: 1985-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: W Blair Geho. Retrieved from https://idiyas.com/inventor/w-blair-geho

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 15)

% Patents Active = 85.3

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 1.8

ph-index = 10

Forward Citations = 1,098(Granted Patents)

Company Filing History:

Technology Unlimited, Inc.

patents

1 out of 1

Diasome Pharmaceuticals, Inc.

5. 3 out of 834,513

Other

patents

Years Active: 1985-2026

Loading Chart...

Areas of Expertise:

Lipid-Based Nanoparticles

Insulin Delivery

Targeted Liposomal Constructs

Bioavailability

Drug Delivery System

Hepatocyte Targeting

Vesicle Delivery

Therapeutic Uses

Diagnostic Applications

Orally Bioavailable Constructs

Diabetic Control

Masking of Liposomes

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12758504 - Compositions comprising lipid-based nanoparticles for treating diabetes mellitus (2026-10-13),

2. 11517529 - Orally bioavailable lipid-based constructs (2022-12-06),

3. 11077173 - Lipid-based nanoparticles and methods using same (2021-08-03),

4. 11071715 - Lipid-based nanoparticles and methods using same (2021-07-27),

5. 10918700 - Lipid-based nanoparticles and use of same in optimized insulin dosing regimens (2021-02-16),

6. 10751418 - Orally bioavailable lipid-based constructs (2020-08-25),

7. 10568835 - Orally bioavailable lipid-based constructs (2020-02-25),

8. 10463616 - Lipid construct for delivery of insulin to a mammal (2019-11-05),

9. 10004686 - Lipid construct for delivery of insulin to a mammal (2018-06-26),

10. 9943602 - Orally bioavailable lipid-based constructs (2018-04-17),

11. 9145453 - Orally bioavailable lipid-based constructs (2015-09-29),

12. 9034372 - Lipid construct for delivery of insulin to a mammal (2015-05-19),

13. 8962015 - Orally bioavailable lipid-based constructs (2015-02-24),

14. 8846053 - Orally bioavailable lipid-based constructs (2014-09-30),

15. 8303983 - Targeted liposomal drug delivery system (2012-11-06),

Title: W Blair Geho: Innovator in Lipid-Based Therapeutics

Introduction

W Blair Geho, based in Wooster, OH, is an accomplished inventor with an impressive portfolio of 33 patents. His innovations primarily focus on lipid-based constructs that enhance the delivery of therapeutic agents, significantly impacting the fields of medicine and biotechnology.

Latest Patents

Among his latest contributions to the industry, Geho developed a patent titled "Orally bioavailable lipid-based constructs." This invention introduces a composition capable of transporting typically non-orally available therapeutic or diagnostic agents through the digestive tract, enhancing their bioavailability. The composition can target specific cellular receptors like hepatocytes, allowing for a more effective delivery of agents such as insulin, calcitonin, and serotonin. Another notable patent is "Lipid-based nanoparticles and methods using same," which offers an improved design of lipid-based nanoparticles for delivering therapeutic agents to mammals, including humans. This innovative nanoparticle features reduced aggregation properties compared to previous iterations, making it a valuable tool in drug delivery systems.

Career Highlights

Throughout his career, Geho has been associated with companies such as SDG LLC and Technology Unlimited, Inc., where he showcased his expertise in creating innovative solutions in the pharmaceutical space. His work has contributed to advancements that bridge the gap between complex therapeutic formulations and practical medical applications.

Collaborations

Geho has collaborated with talented professionals in the field, including coworkers like John R Lau and Joseph Sajan Jacob. These collaborations have enriched his research endeavors and enabled the development of pioneering technologies in drug delivery.

Conclusion

W Blair Geho's contributions to the realm of lipid-based therapeutics reflect his dedication to innovation and improvement in healthcare solutions. His patents not only advance scientific understanding but also pave the way for more effective and accessible therapeutic options for patients worldwide. As the field of biotechnology evolves, Geho's ongoing work will undoubtedly continue to play a crucial role in shaping future advancements.

Profile summary based on public USPTO records.